<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469595</url>
  </required_header>
  <id_info>
    <org_study_id>01-20-005</org_study_id>
    <nct_id>NCT04469595</nct_id>
  </id_info>
  <brief_title>A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)</brief_title>
  <acronym>NEW DAY</acronym>
  <official_title>A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alimera Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alimera Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, masked, active-controlled, parallel-group, multi-center study that will&#xD;
      assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME&#xD;
      (CI-DME). The study will enroll patients who are either treatment naïve or have not received&#xD;
      any DME treatments for the preceding 12 months as documented in medical records. Patients who&#xD;
      received DME treatment &gt;12 months before screening, must not have received &gt;4 intravitreal&#xD;
      injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19&#xD;
      mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL),&#xD;
      compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal&#xD;
      injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as&#xD;
      needed per protocol criteria (2 mg/0.05 mL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, masked, active-controlled, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean total number of supplemental aflibercept injections needed during the study</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>The mean total number of supplemental aflibercept injections needed during</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 15, 10 and 5 letter (ETDRS) gains from baseline</measure>
    <time_frame>At 18 months</time_frame>
    <description>Proportion of subjects with 15, 10 and 5 letter (ETDRS) gains from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>Area under the curve (AUC) of Best Corrected Visual Acuity (BCVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Center Subfield Thickness (CST)</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>Mean change from baseline in Center Subfield Thickness (CST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of Center Subfield Thickness (CST)</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>Area under the curve (AUC) of Center Subfield Thickness (CST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score and subscale scores</measure>
    <time_frame>At 18 months</time_frame>
    <description>The NEI VFQ-25 is a questionnaire that allows the individual to report on their level of visual function. Scores range from 0-100, with a score of 0 being the worst outcome and 100 being the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome Endpoints: The incidence and severity of treatment-related adverse events</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>The incidence and severity of treatment-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>ILUVIEN Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal ILUVIEN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal aflibercept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iluvien 0.19 MG Drug Implant</intervention_name>
    <description>0.19 mg Fluocinolone Acetonide Intravitreal Implant</description>
    <arm_group_label>ILUVIEN Arm</arm_group_label>
    <other_name>ILUVIEN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection</description>
    <arm_group_label>Aflibercept Arm</arm_group_label>
    <arm_group_label>ILUVIEN Arm</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥18 years of age at the time of consent.&#xD;
&#xD;
          2. Must have CI-DME confirmed by Spectral Domain Ocular Coherence Tomography (SD-OCT) and&#xD;
             Center Subfield Thickness (CST) of: ≥350 µm in the study eye.&#xD;
&#xD;
          3. Best Corrected Visual Acuity (BCVA) of ≤80 ETDRS Letters and ≥35 ETDRS letters in the&#xD;
             study eye at Screening Visit.&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          1. Patients with Proliferative Diabetic Retinopathy (PDR); high risk proliferative&#xD;
             diabetic retinopathy in the study eye and related complications.&#xD;
&#xD;
          2. History or current diagnosis of glaucoma or ocular hypertension (OHT) or a cup to disc&#xD;
             ratio &gt;0.8; History of uncontrolled intraocular pressure (defined as IOP ≥25 mmHg with&#xD;
             maximum topical and systemic medical hypotensive treatment) or previous filtration&#xD;
             surgery in the study eye at Screening Visit.&#xD;
&#xD;
          3. Other conditions that can cause macular edema.&#xD;
&#xD;
          4. Patients who received prior LASER photocoagulation therapy including macular grid or&#xD;
             pan retina photocoagulation (PRP) at any time in the study eye. Prior focal LASER&#xD;
             photocoagulation therapy outside the macula is allowed.&#xD;
&#xD;
          5. Patients who received the following therapies in the last 12 months prior to&#xD;
             screening:&#xD;
&#xD;
               1. Intravitreal or periocular steroids in the study eye;&#xD;
&#xD;
               2. Any intravitreal anti-VEGF [vascular endothelial growth factor (VEGF)] (including&#xD;
                  but not limited to bevacizumab, ranibizumab, or aflibercept);&#xD;
&#xD;
               3. Patients who received intravitreal anti-VEGF or corticosteroids &gt;12 months prior&#xD;
                  to the Screening Visit will be allowed in the study, provided that they have not&#xD;
                  received a total of &gt;4 injections.&#xD;
&#xD;
          6. Patients who have lens opacities due to cataract or other etiologies that would make&#xD;
             it difficult to examine the fundus or that affect the patients Activities of Daily&#xD;
             Living (ADL).&#xD;
&#xD;
          7. Steroid Challenge Exclusion Criterion- At the Baseline Visit, patients who are&#xD;
             determined to have an IOP ≥25 mmHg or an increase ≥8 mmHg from Screening will be&#xD;
             excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samer Kaba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alimera Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Nelson</last_name>
    <phone>6785271317</phone>
    <email>rachel.nelson@alimerasciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liz Michael</last_name>
    <phone>6785271764</phone>
    <email>liz.michael@alimerasciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Lemont</city>
        <state>Illinois</state>
        <zip>60439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>72815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Warrenton</city>
        <state>Virginia</state>
        <zip>20186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DME</keyword>
  <keyword>CI-DME</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

